- Llorens-Revull, Meritxell
- Martínez-González, Brenda
- Quer, Josep
- Esteban, Juan Ignacio
- Núñez-Moreno, Gonzalo
- Mínguez, Pablo
- Burgui, Idoia
- Ramos-Ruiz, Ricardo
- Soria, María Eugenia
- Rico, Angie
- Riveiro-Barciela, Mar
- Sauleda, Silvia
- Piron, María
- Corrales, Irene
- Borràs, Francesc E.
- Rodríguez-Frías, Francisco
- Rando, Ariadna
- Ramírez-Serra, Clara
- Camós, Silvia
- Domingo, Esteban
- Bes, Marta
- Perales, Celia
- Costafreda, María Isabel
MicroRNAs (miRNAs) encapsulated in extracellular vesicles (EVs) are potential diagnostic and prognostic biomarkers. However, discrepancies in miRNA patterns and their validation are still frequent due to differences in sample origin, EV isolation, and miRNA sequencing methods. The aim of the present study is to find a reliable EV isolation method for miRNA sequencing, adequate for clinical application. To this aim, two comparative studies were performed in parallel with the same human plasma sample: (i) isolation and characterization of EVs obtained using three procedures: size exclusion chromatography (SEC), iodixanol gradient (GRAD), and its combination (SEC+GRAD) and (ii) evaluation of the yield of miRNA sequences obtained using NextSeq 500 (Illumina) and three miRNA library preparation protocols: NEBNext, NEXTFlex, and SMARTer smRNA-seq. The conclusion of comparison (i) is that recovery of the largest amount of EVs and reproducibility were attained with SEC, but GRAD and SEC+GRAD yielded purer EV preparations. The conclusion of (ii) is that the NEBNext library showed the highest reproducibility in the number of miRNAs recovered and the highest diversity of miRNAs. These results render the combination of GRAD EV isolation and NEBNext library preparation for miRNA retrieval as adequate for clinical applications using plasma samples., This study was funded by Instituto de Salud Carlos III, co-financed by the European Regional Development Fund (ERDF): grant numbers PI18/00210, PI19/00301, PI19/00533, PI21/00139, and PI22/00258; Centro para el Desarrollo Tecnológico Industrial (CDTI) from the Spanish Ministry of Economy and Business, grant number IDI-20200297. The work at CBMSO was supported by grants SAF2014-52400-R from Ministerio de Economía y Competitividad (MINECO), SAF2017-87846-R and BFU2017-91384-EXP from Ministerio de Ciencia, Innovación y Universidades (MCIU), project 525/C/2021 from Fundaciό La Maratό de TV3, PID2020-113888RB-I00, PID2021-126447OB-I00, and 202220I116 from Ministerio de Ciencia e Innovaciόn (MICINN), S2013/ABI-2906 (PLATESA from Comunidad de Madrid/FEDER), and S2018/BAA-4370 (PLATESA2 from Comunidad de Madrid/FEDER). This research work was also funded by the European Commission–NextGenerationEU (regulation EU 2020/2094) through the CSIC’s Global Health Platform (PTI Salud Global). C.P. is supported by the Miguel Servet program of the Instituto de Salud Carlos III (CP14/00121 and CPII19/00001), co-financed by the European Regional Development Fund (ERDF). M.LL. is a recipient of a pre-doctoral fellowship from Instituto de Salud Carlos III (FI20/00313), co-financed by the European Regional Development Fund (ERDF). B.M.-G. is supported by pre-doctoral contract PFIS FI19/00119 from ISCIII, co-financed by Fondo Social Europeo (FSE), “El FSE invierte en tu futuro”. CIBERehd (Centro de Investigación en Red de Enfermedades Hepáticas y Digestivas) is funded by ISCIII. Institutional grants from the Fundación Ramón Areces and Banco Santander to the CBMSO are also acknowledged. The team at CBMSO belongs to the Global Virus Network (GVN)., Peer reviewed